Cancer Antigen Articles & Analysis
45 news found
BCR is defined as rising prostate-specific antigen (PSA) levels with a doubling time of after primary treatment (surgery or radiotherapy).1,2 Darolutamide is already approved under the brand name NubeqaTM for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease as well ...
ByBayer AG
NextPoint’s programs aim to deliver monotherapies for cancer patients without viable treatment options. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Similar to PD-L1, the tumor antigen HHLA2 is a ...
ByBayer AG
(“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRPα monoclonal antibody ES004, PD-L1/SIRPα bispecific antibody ES019, anti-LILRB2 ...
According to the official speaker from Creative BioMart, based on MHC-like complexes that can directly identify and isolate antigen-specific T cells or screen and identify MHC-like antigens that can be used for vaccine development, the company can provide two therapeutic development services: cell therapy and vaccine development. ...
The most recent performance data on Cancer Targeted Technology’s (CTT) leading drugs, CTT1057 and CTT1403, in prostate cancer clinical and preclinical studies will be presented at several scientific and business meetings in June and one that took place in April, the company announced in a press release. ...
LOS ANGELES, CA – October 6, 2022 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the National Cancer Institute (NCI) and Rutgers University sites are open to recruit patients for the treatment of Kita-Kyushu lung cancer ...
Ardigen, one of the world-leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Prof. Dr. Michael Schmitt, MHBA, has joined the company’s Scientific Advisory Board. His knowledge and experience will support work on artificial intelligence-based platforms, dedicated to accelerating and optimizing the discovery of novel cell ...
ByArdigen
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type. ...
The presentations highlight new data related to the application of gene circuit technology to enhance efficacy and safety of cancer-killing allogeneic chimeric antigen receptor (CAR) natural killer (NK) cells. ...
“Clinical data previously collected by Cancer Research UK demonstrated peripheral immunogenicity in patients with NSCLC treated with VAC2, providing support to the underlying mechanism of using allogeneic dendritic cells to present tumor-associated antigens to the body’s immune system. ...
“Specifically, the ability of our technology to target tumor self-antigens and induce a potent T cell response that leads to tumor regression is important as we prepare to file an IND for our HB-300 program in prostate cancer in the third quarter. ...
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present preclinical data highlighting its cytoTIL15™ program during a poster session at the upcoming AACR Annual Meeting 2022. The abstract title has been posted to the AACR Online Itinerary Planner, will be published in the online Proceedings of the AACR, and is ...
This is achieved by delivering a DNA plasmid using Ichor’s TriGrid® 2.0 electroporation delivery device to enhance the uptake and presentation of cancer antigens to harness high avidity T cell responses. In a Phase 1/2 clinical trial, survival following SCIB1 monotherapy was superior to historical survival rates, with 14 of 16 resected patients ...
ByScancell
Carina Biotech is very pleased to announce that we have submitted a pre-IND (Investigational New Drug) application to the US FDA (Food & Drug Administration) for our CAR-T therapy that targets a cancer stem cell antigen known as LGR5. This represents a major step towards taking our CAR-T cell (CNA3103) into a Phase I/IIa clinical trial in patients with ...
Basel, March 23, 2022 — Novartis announced today that the US Food and Drug Administration (FDA) approved PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castrationresistant ...
Combining Zephyr’s proprietary artificial intelligence (AI) and algorithmic technology with NexImmune’s Artificial Immune Modulation (AIM) nanoparticle technology, the collaboration will seek to identify and validate optimal antigens and antigen cocktails for the development of potential new therapeutics in solid and hematological ...
(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute ...
VAXIMM technology enables fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by the neoantigen field NEC OncoImmunity to initiate first clinical trial with lead program from acquisition in 2022 Oslo (Norway)/Tokyo (Japan) and Basel (Switzerland)/Mannheim (Germany) - March 8, 2022: NEC OncoImmunity (NOI), a subsidiary of NEC ...
The published article on the study, Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results from a single institution, was authored by Joshua L. ...
We will now use this unique addition to our bioinformatics toolbox to further characterize the relationship between variation in HLA alleles and response to cancer immunotherapy.” Said, Dr. Trevor Clancy, Chief Scientific Officer at NEC OncoImmunity. References Title: Personalized HLA typing leads to the discovery of novel HLA alleles and tumor-specific HLA variants ...